Vraylar, also known as cariprazine, is being considered for treatment of major depressive disorder and schizophrenia. The medication's dosage and timing are being examined, with discussions on optimal dosing and potential side effects. Its effectiveness as an adjunctive treatment for major depressive disorder has been approved, and it is also being looked at as an option for patients who do not respond to traditional antidepressants.